

# Carestream Molecular Imaging

REC RG1 OCT 10 '12 AM 07:47

Carestream Molecular Imaging  
4 Research Drive  
Woodbridge, CT 06525

October 02rev, 2012

Judith A. Joustra, Chief  
Commercial and R&D Branch  
Division of Nuclear Materials Safety  
U.S. Nuclear Regulatory Commission, Region 1  
2100 Renaissance Blvd, Suite 100  
King of Prussia, PA 19406-2713  
RE: Materials License 06-21254-01

Br 2

03020106

This letter is to notify you of a change in control of our materials license. Our company (Carestream Molecular Imaging, Carestream Health, Inc.) has been sold to Bruker Biospin Corporation. Further, the RSO position is being transferred from Douglas Vizard, PhD to John Pizzonia, PhD. Note that John Pizzonia is currently listed as assistant RSO on the license, and has extensive experience (documented in license application).


The appropriately amended license should designate "Bruker Biospin Corporation" as the controlling party, and John Pizzonia, PhD as the RSO. The address, facility, practice and particulars of the license remain the same.

Please advise should more information or a different format for the application be needed.

Douglas L. Vizard, PhD  
John Pizzonia, PhD, RSO  
Molecular Imaging Systems, Carestream Health, Inc.  
4 Science Park West  
New Haven, CT 06525  
(203) 786-5663  
[john.pizzonia@carestream.com](mailto:john.pizzonia@carestream.com)

Copy:  
Mark Chaykovsky, EVP  
Bruker Biospin Corporation  
15 Fortune Drive  
Billerica, MA 01821  
Tel: (978)-663-3660

Respectfully,



John Pizzonia, PhD, RSO

579239

NMSS/RGN1 MATERIALS-002

# Carestream Molecular Imaging

Carestream Molecular Imaging  
4 Research Drive  
Woodbridge, CT 06525

SOURCED FROM [nrc.gov/electronic reading/document collection/NUREG](http://nrc.gov/electronic%20reading/document%20collection/NUREG)  
**NUREG-1556, Vol. 7, 8.2 (Timely Notification of Transfer of Control).**

## Appendix E: Information Needed for Transfer of Control Application

### Information Needed for Transfer of Control Application

Licensees must provide full information and obtain NRC's *prior written consent* before transferring control of the license; some licensees refer to this as "transferring the license." Provide the following information concerning changes of control by the applicant (transferor and/or transferee, as appropriate). If any items are not applicable, so state.

1. The new name of the licensed organization. If there is no change, the licensee should so state. **Bruker Biospin Corporation.**
2. The new licensee contact and telephone number(s) to facilitate communications. **John Pizzonia, PhD, (203) 786-5663**
3. Any changes in personnel having control over licensed activities (e.g., officers of a corporation) and any changes in personnel named in the license such as radiation safety officer, authorized users, or any other persons identified in previous license applications as responsible for radiation safety or use of licensed material. The licensee should include information concerning the qualifications, training, and responsibilities of new individuals. **RSO change from Douglas Vizard to John Pizzonia.**
4. An indication of whether the transferor will remain in non-licensed business without the license. **SEPARATE LICENSE, STATE OF NEW YORK.**
5. A complete, clear description of the transaction, including any transfer of stocks or assets, mergers, etc., so that legal counsel is able, when necessary, to differentiate between name changes and transferring control. **On September 21, 2012 Carestream Health (a subsidiary of Onex Corporation) and Bruker Bio Spin Corporation have entered into an agreement for Bruker to purchase the preclinical in-vivo imaging equipment product portfolio and related assets from Carestream Health's Molecular Imaging business. Under the terms of the agreement, at the closing on October 1, 2012 Carestream Health transferred to Bruker Biospin, and Bruker Biospin assumed, substantially all of Carestream's rights and obligations related to the Molecular Imaging group. Bruker Biospin Corporation, a Massachusetts corporation, has its primary offices in Billerica, located at 15 Fortune Drive, Billerica, MA 01821.**
6. A complete description of any planned changes in organization, location, facility, equipment, or procedures (i.e., changes in operating or emergency procedures). **NONE ANTICIPATED.**
7. A detailed description of any changes in the use, possession, location, or storage of the licensed materials. **NONE ANTICIPATED.**
8. Any changes in organization, location, facilities, equipment, procedures, or personnel that would require a license amendment even without transferring control. **Change in RSO from Douglas Vizard, PhD to John Pizzonia, PhD.**
9. An indication of whether all surveillance items and records (e.g., calibrations, leak tests, surveys, inventories, and accountability requirements) will be current at the time of transfer. Provide a description of the status of all surveillance requirements and records. **CURRENT, NO MATERIALS IN USE.**

# Carestream Molecular Imaging

Carestream Molecular Imaging  
4 Research Drive  
Woodbridge, CT 06525

10. Confirmation that all records concerning the safe and effective decommissioning of the facility, pursuant to 10 CFR 30.35(g), 40.36(f), 70.25(g), and 72.30(d); public dose; and waste disposal by release to sewers, incineration, radioactive material spills, and on-site burials, have been transferred to the new licensee, if licensed activities will continue at the same location, or to NRC for license terminations. **RECORDS INTACT, NO TRANSFER ANTICIPATED, ANTICIPATE NO CHANGE IN LOCATION/ACTIVITIES.**

11. A description of the status of the facility. Specifically, the presence or absence of contamination should be documented. If contamination is present, will decontamination occur before transfer? If not, does the successor company agree to assume full liability for the decontamination of the facility or site? **NO CONTAMINATION DETECTED, ALL MATERIALS DECAYED IN STORAGE.**

12. A description of any decontamination plans, including financial assurance arrangements of the transferee, as specified in 10 CFR 30.35, 40.36, and 70.25. Include information about how the transferee and transferor propose to divide the transferor's assets, and responsibility for any cleanup needed at the time of transfer. **NONE ANTICIPATED.**

13. Confirmation that the transferee agrees to abide by all commitments and representations previously made to NRC by the transferor. These include, but are not limited to: maintaining decommissioning records required by 10 CFR 30.35(g); implementing decontamination activities and decommissioning of the site; and completing corrective actions for open inspection items and enforcement actions.

With regard to contamination of facilities and equipment, the transferee should confirm, in writing, that it accepts full liability for the site, and should provide evidence of adequate resources to fund decommissioning; or the transferor should provide a commitment to decontaminate the facility before transferring control.

With regard to open inspection items, etc., the transferee should confirm, in writing, that it accepts full responsibility for open inspection items and/or any resulting enforcement actions; or the transferee proposes alternative measures for meeting the requirements; or the transferor provides a commitment to close out all such actions with NRC before license transfer. **ATTEST.**

14. Documentation that the transferor and transferee agree to transferring control of the licensed material and activity, and the conditions of transfer; and the transferee is made aware of all open inspection items and its responsibility for possible resulting enforcement actions. **ATTEST.**

15. A commitment by the transferee to abide by all constraints, conditions, requirements, representations, and commitments identified in the existing license. If not, the transferee must provide a description of its program, to ensure compliance with the license and regulations.

**ATTEST.**

**Reference:** See the Notice of Availability on the inside front cover of this report to obtain copies. Information Notice 89-25, Revision 1, "Unauthorized Transfer of Ownership or Control of Licensed Activities."

This is to acknowledge the receipt of your letter/application dated

10-02-12, and to inform you that the initial processing which includes an administrative review has been performed.

Amend: 06-21254-01  
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

---

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 579239.  
When calling to inquire about this action, please refer to this control number.  
You may call us on (610) 337-5398, or 337-5260.